Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

DNA damage sensor γ -H2AX is increased in preneoplastic lesions of hepatocellular carcinoma.

Matsuda Y, Wakai T, Kubota M, Osawa M, Takamura M, Yamagiwa S, Aoyagi Y, Sanpei A, Fujimaki S.

ScientificWorldJournal. 2013;2013:597095. doi: 10.1155/2013/597095. Epub 2013 Mar 3.

2.

Large liver cell change in hepatitis B virus-related liver cirrhosis.

Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN.

Hepatology. 2009 Sep;50(3):752-62. doi: 10.1002/hep.23072.

PMID:
19585549
3.

The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.

Yeh MM, Larson AM, Campbell JS, Fausto N, Rulyak SJ, Swanson PE.

Am J Surg Pathol. 2007 May;31(5):681-9.

PMID:
17460450
4.

Increased expression of stathmin and elongation factor 1α in precancerous nodules with telomere dysfunction in hepatitis B viral cirrhotic patients.

Ahn EY, Yoo JE, Rhee H, Kim MS, Choi J, Ko JE, Lee JS, Park YN.

J Transl Med. 2014 May 31;12:154. doi: 10.1186/1479-5876-12-154.

5.

Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.

Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, Hadziyannis S.

J Viral Hepat. 2005 Nov;12(6):635-41.

PMID:
16255765
6.

New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.

Göbel T, Vorderwülbecke S, Hauck K, Fey H, Häussinger D, Erhardt A.

World J Gastroenterol. 2006 Dec 21;12(47):7604-12.

7.

[Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].

Tátrai P.

Magy Onkol. 2008 Dec;52(4):379-83. doi: 10.1556/MOnkol.52.2008.4.7. Hungarian.

PMID:
19068466
8.

Proteomic dissection of cell type-specific H2AX-interacting protein complex associated with hepatocellular carcinoma.

Yang X, Zou P, Yao J, Yun D, Bao H, Du R, Long J, Chen X.

J Proteome Res. 2010 Mar 5;9(3):1402-15. doi: 10.1021/pr900932y.

9.

HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma.

Momosaki S, Nakashima Y, Kojiro M, Tabor E.

J Viral Hepat. 2005 May;12(3):325-9.

PMID:
15850475
10.

Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis.

Jakate S, Yabes A, Giusto D, Naini B, Lassman C, Yeh MM, Ferrell LD.

Am J Surg Pathol. 2010 Jul;34(7):935-41. doi: 10.1097/PAS.0b013e3181ddf52f.

PMID:
20463569
11.

Computer-aided assessment of hepatic contour abnormalities as an imaging biomarker for the prediction of hepatocellular carcinoma development in patients with chronic hepatitis C.

Goshima S, Kanematsu M, Kondo H, Watanabe H, Noda Y, Fujita H, Bae KT.

Eur J Radiol. 2015 May;84(5):811-5. doi: 10.1016/j.ejrad.2015.01.009. Epub 2015 Jan 22.

PMID:
25650331
12.

Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.

Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R.

Am J Gastroenterol. 2000 Apr;95(4):1036-40.

PMID:
10763956
13.

Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.

El-Bassiouny AE, Zoheiry MM, Nosseir MM, El-Ahwany EG, Ibrahim RA, El-Bassiouni NE.

MedGenMed. 2007 Aug 28;9(3):45.

14.

Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.

Mondal G, Saroha A, Bose PP, Chatterjee BP.

Glycoconj J. 2016 Apr;33(2):209-18. doi: 10.1007/s10719-016-9658-2. Epub 2016 Mar 31.

PMID:
27034286
15.

Detection of hepatocellular carcinoma using glycomic analysis.

Goldman R, Ressom HW, Varghese RS, Goldman L, Bascug G, Loffredo CA, Abdel-Hamid M, Gouda I, Ezzat S, Kyselova Z, Mechref Y, Novotny MV.

Clin Cancer Res. 2009 Mar 1;15(5):1808-13. doi: 10.1158/1078-0432.CCR-07-5261. Epub 2009 Feb 17.

16.

Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.

Passos-Castilho AM, Lo Turco E, Ferraz ML, Matos C, Silva I, Parise E, Pilau E, Gozzo F, Granato C.

J Gastrointestin Liver Dis. 2015 Mar;24(1):43-9. doi: 10.15403/jgld.2014.1121.pas.

17.

Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma.

Ying X, Zhao Y, Wang JL, Zhou X, Zhao J, He CC, Guo XJ, Jin GH, Wang LJ, Zhu Q, Han SX.

Oncol Rep. 2014 Oct;32(4):1550-6. doi: 10.3892/or.2014.3367. Epub 2014 Jul 30.

PMID:
25109745
18.

Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma.

Noh CK, Kim SS, Kim DK, Lee HY, Cho HJ, Yoon SY, Lee GH, Hyun SA, Kim YJ, Kim HJ, Hwang JA, Ahn SJ, Shin SJ, Lee KM, Yoo BM, Cho SW, Cheong JY.

Clin Biochem. 2014 Sep;47(13-14):1257-61. doi: 10.1016/j.clinbiochem.2014.05.002. Epub 2014 May 14.

PMID:
24836184
19.

Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?

Kara B, Doran F, Kara IO, Akkiz H, Sandikci M.

Int J Clin Pract. 2008 Aug;62(8):1206-11. doi: 10.1111/j.1742-1241.2007.01675.x. Epub 2008 Feb 18.

PMID:
18284441
20.

Chronic viral hepatitis and hepatocellular carcinoma.

Barazani Y, Hiatt JR, Tong MJ, Busuttil RW.

World J Surg. 2007 Jun;31(6):1243-8.

PMID:
17440771

Supplemental Content

Support Center